Upload
hayden-maldonado
View
212
Download
0
Tags:
Embed Size (px)
Citation preview
PRESCRIPTION AUDIT PRESCRIPTION AUDIT AND ADR PROFILE IN AND ADR PROFILE IN PATIENTS WITH LUNG PATIENTS WITH LUNG
CARCINOMACARCINOMAJitendra SJitendra S, Aruna Bhaskar, Shoba Guido, , Aruna Bhaskar, Shoba Guido,
RadheyshyamRadheyshyamDept.of Pharmacology,Dept.of Pharmacology,
St.Johns Medical College,St.Johns Medical College,BangaloreBangalore
Lung carcinoma accounts for Lung carcinoma accounts for the total of 30% of the cancers the total of 30% of the cancers and 28% of the cancer deaths.and 28% of the cancer deaths.
Chemotherapy is a part of Chemotherapy is a part of multi-modality treatment in multi-modality treatment in these patients.these patients.
ADRs happen to be a common ADRs happen to be a common occurrence in patients on occurrence in patients on chemotherapy.chemotherapy.
INTRODUCTIONINTRODUCTION
OBJECTIVES -OBJECTIVES -
To see for the prescription To see for the prescription pattern of anti-cancer drugs with pattern of anti-cancer drugs with lung carcinoma.lung carcinoma.
To look for associated ADRs and To look for associated ADRs and to define them in accordance to define them in accordance with causality assessment.with causality assessment.
MATERIALS AND MATERIALS AND METHODSMETHODS It is a retrospective study It is a retrospective study
carried out from Aug 2001-carried out from Aug 2001-Sep 2006.Sep 2006.
Data was collected and Data was collected and subjected to Simple subjected to Simple descriptive analysis.descriptive analysis.
RESULTS…..RESULTS…..
Total no. of cases treated on Total no. of cases treated on out-patient basis in five years out-patient basis in five years was 68.was 68.
Male : female ratio was 2.5:1.Male : female ratio was 2.5:1. Age range was from 34-70 Age range was from 34-70
yrs, average being 55 years.yrs, average being 55 years. 80% were smokers.80% were smokers.
Outcome on Outcome on consultation.consultation.
0 10 20 30 40 50
RECEIVEDT/ X
DAMA
REFERRED
EXPIRED
Average no. of drugs per Average no. of drugs per prescription was 3.55.prescription was 3.55.
The maximum drugs prescribed The maximum drugs prescribed in a given prescription was 11.in a given prescription was 11.
Generic prescription accounted Generic prescription accounted for 30% of prescribed drugs.for 30% of prescribed drugs.
HISTOPATHOLOGICALLY HISTOPATHOLOGICALLY DIAGNOSED CASESDIAGNOSED CASES
Adeno65%
Squamous22%
Bronchial10%
Large3%
Modality of treatmentsModality of treatments
20
11
84
CT CT+RT PALLV SUR+CT
ASSO. OF T/T WITH ASSO. OF T/T WITH DIAGNOSISDIAGNOSIS
0
5
10
15
20
25
30
35
TR
EAT
ME
NT
CT RT CT+RT SU+RT+CTADEN SQU BRO LAR
PRESCRIPTION PATTERN PRESCRIPTION PATTERN OF DRUGSOF DRUGS
26%
18%
16%
8% 8% 2%
AN-CAN AN-EMETIC STEROIDAN-ULCER HYPNOTIC BNP
PRESCRIPTION IN PRESCRIPTION IN DIFFERENT GROUP OF DIFFERENT GROUP OF
DRUGSDRUGS
50% 43%57%
37%33%
5%
43%
13%24%
95%
0%
20%
40%
60%
80%
100%
120%
AN-CANCER AN-ULCER AN-EMETIC STEROID
PATTERN OF ANTI-PATTERN OF ANTI-CANCER DRUGS CANCER DRUGS
PRESCRIBEDPRESCRIBED57
78
32
108
3
GEM CAR+ETO CARCAR+DOC DOC GEM+CAR
ADR PROFILE….ADR PROFILE….
ADRs were reported in 40% of ADRs were reported in 40% of treated patients.treated patients.
Type A was the most common type.Type A was the most common type.
Hematological adverse events were Hematological adverse events were seen in 70%, GIT 20%,Skin in 10%.seen in 70%, GIT 20%,Skin in 10%.
SYSTEMIC ADRSSYSTEMIC ADRS
0%
10%
20%
30%
40%
50%
60%
70%
BLOOD SKIN CNS
HAEHAE GEMGEM CAR+CAR+
ETOETOCARCAR PAC+PAC+
CARCARDOCDOC DOC+DOC+
CARCARGEMGEM+CAR+CAR
HBHB%%
2(8.2(8.1)1)
2(62(6))
1(8)1(8) 1(8)1(8)
WBWBCC
2(1.2(1.7)7)
1(1.21(1.2))
1(2)1(2)
MYMYEE
22 66 11 33 22
PLAPLA 2(542(54))
1(30)1(30) 1(8)1(8)
HAEMATOLOGY HAEMATOLOGY MANIFESTATIONSMANIFESTATIONS
NON HAEMATOLOGICAL NON HAEMATOLOGICAL MANIFESTATIONSMANIFESTATIONS
GEMGEM ETO+ETO+CARCAR
CARCAR PAC+PAC+
CARCARDOCDOC DOC+DOC+
CARCARCAR+CAR+GEMGEM
DIADIA 88 11
VOVOMM
33 44 22 55 1313 44 22
SKISKINN
44 11 11
CNSCNS 22 22
CVS CVS 11 11 11
CAUSALITY CAUSALITY ASSESSMENTASSESSMENT
4%12%
84%
CER PRO POS
DISCUSSIONDISCUSSION
THERE IS A PREDOMINANCE OF THERE IS A PREDOMINANCE OF LUNG CARCINOMA AMONG LUNG CARCINOMA AMONG ELDERLY MALE.ELDERLY MALE.
POLYPHARMACY IS LARGELY POLYPHARMACY IS LARGELY PRACTISED IN PRESCRIPTIONS.PRACTISED IN PRESCRIPTIONS.
CHEMOTHEARPY IS THE CHEMOTHEARPY IS THE COMMON MODALITY OF COMMON MODALITY OF TREATMENT AND PREFERABLY TREATMENT AND PREFERABLY USED IN ADENOCARCINOMA.USED IN ADENOCARCINOMA.
GEMCITABINE IS PREFFERED GEMCITABINE IS PREFFERED NOW. NOW.
PANTAPRAZOLE IS PREFFERED PANTAPRAZOLE IS PREFFERED OVER ESMOPRAZOLE.OVER ESMOPRAZOLE.
HAEMATOLOGICAL HAEMATOLOGICAL MANIFESTATIONS ARE COMMON MANIFESTATIONS ARE COMMON WITH GEMCITABINE.WITH GEMCITABINE.
VOMITING AND CARDIAC VOMITING AND CARDIAC MANIFESTATIONS ARE SEEN MANIFESTATIONS ARE SEEN WITH DOCETAXEL.WITH DOCETAXEL.
POSSIBLE ADVERSE REACTIONS POSSIBLE ADVERSE REACTIONS WERE MOST COMMON IN WERE MOST COMMON IN ACCORDANCE WITH CAUSALITY ACCORDANCE WITH CAUSALITY ASSESSMENT.ASSESSMENT.
CONCLUSIONCONCLUSION
SMOKING IS A RISK FACTOR SMOKING IS A RISK FACTOR FOR LUNG CARCINOMA.FOR LUNG CARCINOMA.
POLYPHARMACY IS PRACTISED TO POLYPHARMACY IS PRACTISED TO REDUCE THE ADVERSE DRUG REDUCE THE ADVERSE DRUG REACTIONS.REACTIONS.
GEMCITABINE AND GEMCITABINE AND PANTAPRAZOLE ARE THE NEWLY PANTAPRAZOLE ARE THE NEWLY PREFFERED DRUGS IN PREFFERED DRUGS IN REGIMENS BECAUSE OF BETTER REGIMENS BECAUSE OF BETTER EFFICACY AND TOLERABILITY.EFFICACY AND TOLERABILITY.
THANK YOU……..THANK YOU……..